Citigroup
CLVS

Citigroup’s Clovis Oncology, Inc. CLVS Stock Holding History

Citigroup’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-62,500
Closed -$300K – 7712
2020
Q4 		$300K Sell
62,500
-36,100
-37% -$183K ﹤0.01% 4661
2020
Q3 		$575K Buy
98,600
+21,100
+27% +$126K ﹤0.01% 3738
2020
Q2 		$523K Buy
77,500
+44,200
+133% +$335K ﹤0.01% 4221
2020
Q1 		$212K Sell
33,300
-36,500
-52% -$293K ﹤0.01% 4680
2019
Q4 		$728K Buy
69,800
+16,100
+30% +$117K ﹤0.01% 4076
2019
Q3 		$211K Buy
53,700
+5,700
+12% +$46.1K ﹤0.01% 5113
2019
Q2 		$714K Buy
48,000
+19,400
+68% +$351K ﹤0.01% 4045
2019
Q1 		$710K Sell
28,600
-6,900
-19% -$173K ﹤0.01% 3784
2018
Q4 		$637K Buy
35,500
+700
+2% +$14.3K ﹤0.01% 3871
2018
Q3 		$1.02M Buy
34,800
+2,600
+8% +$101K ﹤0.01% 3480
2018
Q2 		$1.46M Sell
32,200
-3,400
-10% -$165K ﹤0.01% 2977
2018
Q1 		$1.88M Sell
35,600
-22,700
-39% -$1.32M ﹤0.01% 2645
2017
Q4 		$3.96M Sell
58,300
-12,100
-17% -$846K ﹤0.01% 2059
2017
Q3 		$5.8M Buy
70,400
+27,800
+65% +$2.2M ﹤0.01% 1625
2017
Q2 		$3.99M Buy
42,600
+18,400
+76% +$1.13M ﹤0.01% 1901
2017
Q1 		$1.54M Sell
24,200
-2,500
-9% -$152K ﹤0.01% 2737
2016
Q4 		$1.19M Buy
26,700
+4,400
+20% +$155K ﹤0.01% 3498
2016
Q3 		$804K Buy
22,300
+9,800
+78% +$210K ﹤0.01% 3451
2016
Q2 		$172K Sell
12,500
-40,300
-76% -$589K ﹤0.01% 4627
2016
Q1 		$1.01M Buy
52,800
+45,000
+577% +$952K ﹤0.01% 3324
2015
Q4 		$273K Sell
7,800
-35,700
-82% -$2.3M ﹤0.01% 4458
2015
Q3 		$4M Buy
43,500
+38,400
+753% +$3.32M ﹤0.01% 1851
2015
Q2 		$448K Buy
+5,100
New +$437K ﹤0.01% 3804
2015
Q1 		– Sell
-7,900
Closed -$442K – 7515
2014
Q4 		$442K Hold
7,900
– – ﹤0.01% 3996
2014
Q3 		$358K Hold
7,900
– – ﹤0.01% 3787
2014
Q2 		$327K Buy
+7,900
New +$407K ﹤0.01% 3746

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup's CLVS Position: Q4 2022 in Review

Citigroup sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 1,752 shares — an estimated $2K sold.

Citigroup first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $27.2M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Citigroup reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 1,752 Clovis Oncology, Inc. shares in Q4 2022, an estimated $2K.
  • Citigroup first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Citigroup's Clovis Oncology, Inc. position peaked at $27.2M in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.